Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
Latest From Leadership
In her new role as executive vice president, chief research officer, Sharon Hesterlee brings industry bone fides and nonprofit experiences to bear on tomorrow’s neuromuscular treatments and cures.
The advent of COVID-19 and its effects on care delivery have meant that short-term priorities for health care systems have switched temporarily to public health emergency mode. But the longer-term need to restructure delivery around outcomes and federated data management for patients is here to stay, says Royal Philips’ Jeroen Tas.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
What are the skills future life sciences leaders will need in order to rise to the top of biopharma and medtech companies? A recent BioTrinity industry panel debated the profile of tomorrow’s leaders.
Coaching and mentoring are important tools for the leaders of today to be able to foster the next generation of talent in the biopharma sector. While the routes into industry have not changed dramatically – most leaders hold a master’s degree and/or PhD – the expectations of rising leaders have altered and the industry itself has become more collaborative.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.